EFElina Fredlund

Elina Fredlund

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elina Fredlund has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Elien Hilgert

    Department of Biomolecular Medicine, Faculty of Medicine & Health Sciences, Ghent University; Cancer Research Institute Ghent (CRIG), Ghent, Belgium

    1 shared publication
  • Emma Magnusson

    Division of Pediatrics, Department of Clinical Sciences, Lund University, Lund, Sweden

    1 shared publication
  • Emma U. Hammarlund

    Department of Experimental Medical Science, Lund University, Lund, Sweden

    1 shared publication
  • Enrika Miltenyte

    Division of Pediatrics, Department of Clinical Sciences, Lund University, Lund, Sweden

    1 shared publication
  • Estelle Lecomte

    Division of Pediatrics, Department of Clinical Sciences, Lund University, Lund, Sweden

    1 shared publication
  • Ezequiel Monferrer

    Department of Pathology, Medical School, University of Valencia-INCLIVA Biomedical Health Research Institute, Valencia, Spain

    1 shared publication

Latest Publications

  • Open Access

    MOXD1 is a lineage-specific gene and a tumor suppressor in neuroblastoma

    by Elina Fredlund, Stina Andersson, Elien Hilgert, Ezequiel Monferrer, Guadalupe Álvarez-Hernán, Sinan Karakaya, Siebe Loontiens, Jan Willem Bek, Tomas Gregor, Estelle Lecomte, et al.

    Neuroblastoma is a childhood developmental cancer; however, its embryonic origins remain poorly understood. Moreover, in-depth studies of early tumor-driving events are limited because of the lack of appropriate models. Herein, we analyzed RNA sequencing data obtained from human neuroblastoma samples and found that loss of expression of trunk neural crest–enriched gene MOXD1 associates with advanced disease and worse outcome. Further, by using single-cell RNA sequencing data of human neuroblastoma cells and fetal adrenal glands and creating in vivo models of zebrafish, chick, and mouse, we show that MOXD1 is a determinate of tumor development. In addition, we found that MOXD1 expression is highly conserved and restricted to mesenchymal neuroblastoma cells and Schwann cell precursors during healthy development. Our findings identify MOXD1 as a lineage-restricted tumor-suppressor gene in neuroblastoma, potentiating further stratification of these tumors and development of novel therapeutic interventions.